IDEAS home Printed from https://ideas.repec.org/a/plo/pntd00/0004568.html
   My bibliography  Save this article

Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa

Author

Listed:
  • Muhammad Hamza
  • Maryam A Idris
  • Musa B Maiyaki
  • Mohammed Lamorde
  • Jean-Philippe Chippaux
  • David A Warrell
  • Andreas Kuznik
  • Abdulrazaq G Habib

Abstract

Background: Snakebite poisoning is a significant medical problem in agricultural societies in Sub Saharan Africa. Antivenom (AV) is the standard treatment, and we assessed the cost-effectiveness of making it available in 16 countries in West Africa. Methods: We determined the cost-effectiveness of AV based on a decision-tree model from a public payer perspective. Specific AVs included in the model were Antivipmyn, FAV Afrique, EchiTab-G and EchiTab-Plus. We derived inputs from the literature which included: type of snakes causing bites (carpet viper (Echis species)/non-carpet viper), AV effectiveness against death, mortality without AV, probability of Early Adverse Reactions (EAR), likelihood of death from EAR, average age at envenomation in years, anticipated remaining life span and likelihood of amputation. Costs incurred by the victims include: costs of confirming and evaluating envenomation, AV acquisition, routine care, AV transportation logistics, hospital admission and related transportation costs, management of AV EAR compared to the alternative of free snakebite care with ineffective or no AV. Incremental Cost Effectiveness Ratios (ICERs) were assessed as the cost per death averted and the cost per Disability-Adjusted-Life-Years (DALY) averted. Probabilistic Sensitivity Analyses (PSA) using Monte Carlo simulations were used to obtain 95% Confidence Intervals of ICERs. Results: The cost/death averted for the 16 countries of interest ranged from $1,997 in Guinea Bissau to $6,205 for Liberia and Sierra Leone. The cost/DALY averted ranged from $83 (95% Confidence Interval: $36-$240) for Benin Republic to $281 ($159–457) for Sierra-Leone. In all cases, the base-case cost/DALY averted estimate fell below the commonly accepted threshold of one time per capita GDP, suggesting that AV is highly cost-effective for the treatment of snakebite in all 16 WA countries. The findings were consistent even with variations of inputs in 1—way sensitivity analyses. In addition, the PSA showed that in the majority of iterations ranging from 97.3% in Liberia to 100% in Cameroun, Guinea Bissau, Mali, Nigeria and Senegal, our model results yielded an ICER that fell below the threshold of one time per capita GDP, thus, indicating a high degree of confidence in our results. Conclusions: Therapy for SBE with AV in countries of WA is highly cost-effective at commonly accepted thresholds. Broadening access to effective AVs in rural communities in West Africa is a priority. Author Summary: Antivenom is the main intervention against snakebite poisoning but is relatively scarce, unaffordable and the situation has been compounded further by the recent cessation of production of effective antivenoms and marketing of inappropriate products. Given this crisis, we assessed the cost effectiveness of providing antivenoms in West Africa by comparing costs associated with antivenom treatment against their health benefits in decreasing mortality. In the most comprehensive analyses ever conducted, it was observed the incremental cost effectiveness ratio of providing antivenom ranged from $1,997 in Guinea Bissau to $6,205 for Liberia and Sierra-Leone per death averted while cost per Disability Adjusted Life Year (DALY) averted ranged from $83 for Benin Republic to $281 for Sierra-Leone. There is probability of 97.3–100% that antivenoms are very cost-effective in the analyses. These demonstrate antivenom is highly cost-effective and compares favorably to other commonly funded healthcare interventions. Providing and broadening antivenom access throughout areas at risk in rural West Africa should be prioritized given the considerable reduction in deaths and DALYs that could be derived at a relatively small cost.

Suggested Citation

  • Muhammad Hamza & Maryam A Idris & Musa B Maiyaki & Mohammed Lamorde & Jean-Philippe Chippaux & David A Warrell & Andreas Kuznik & Abdulrazaq G Habib, 2016. "Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 10(3), pages 1-16, March.
  • Handle: RePEc:plo:pntd00:0004568
    DOI: 10.1371/journal.pntd.0004568
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004568
    Download Restriction: no

    File URL: https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0004568&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pntd.0004568?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 367-372, June.
    2. Shehan S Williams & Chamara A Wijesinghe & Shaluka F Jayamanne & Nicholas A Buckley & Andrew H Dawson & David G Lalloo & H Janaka de Silva, 2011. "Delayed Psychological Morbidity Associated with Snakebite Envenoming," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 5(8), pages 1-6, August.
    3. Abdulrazaq G Habib & Mohammed Lamorde & Mahmood M Dalhat & Zaiyad G Habib & Andreas Kuznik, 2015. "Cost-effectiveness of Antivenoms for Snakebite Envenoming in Nigeria," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 9(1), pages 1-7, January.
    4. Nicholas I Brown, 2012. "Consequences of Neglect: Analysis of the Sub-Saharan African Snake Antivenom Market and the Global Context," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 6(6), pages 1-7, June.
    5. S.J. Goldie & Y. Yazdanpanah & E. Losina & M.C. Weinstein & X. Anglaret & R.P. Walensky & H.E. Hsu & A. Kimmel & C. Holmes & J.E. Kaplan & K.A. Freedberg, 2006. "Cost-effectiveness of HIV treatment in Resource-Poor Settings - The case of Côte d'Ivoire," Post-Print hal-00199992, HAL.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Abdulrazaq G Habib & Baba M Musa & Garba Iliyasu & Muhammad Hamza & Andreas Kuznik & Jean-Philippe Chippaux, 2020. "Challenges and prospects of snake antivenom supply in sub-Saharan Africa," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(8), pages 1-10, August.
    2. Sayem Ahmed & Guibehi B Koudou & Maïwenn Bagot & François Drabo & Windtaré R Bougma & Caisey Pulford & Moses Bockarie & Robert A Harrison, 2021. "Health and economic burden estimates of snakebite management upon health facilities in three regions of southern Burkina Faso," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 15(6), pages 1-17, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Abdulrazaq G Habib & Mohammed Lamorde & Mahmood M Dalhat & Zaiyad G Habib & Andreas Kuznik, 2015. "Cost-effectiveness of Antivenoms for Snakebite Envenoming in Nigeria," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 9(1), pages 1-7, January.
    2. Sayem Ahmed & Guibehi B Koudou & Maïwenn Bagot & François Drabo & Windtaré R Bougma & Caisey Pulford & Moses Bockarie & Robert A Harrison, 2021. "Health and economic burden estimates of snakebite management upon health facilities in three regions of southern Burkina Faso," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 15(6), pages 1-17, June.
    3. Giovanna Elisa Calabrò & Sara Boccalini & Donatella Panatto & Caterina Rizzo & Maria Luisa Di Pietro & Fasika Molla Abreha & Marco Ajelli & Daniela Amicizia & Angela Bechini & Irene Giacchetta & Piero, 2022. "The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment," IJERPH, MDPI, vol. 19(7), pages 1-14, March.
    4. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    5. Clarke, Lorcan, 2020. "An introduction to economic studies, health emergencies, and COVID-19," LSE Research Online Documents on Economics 105051, London School of Economics and Political Science, LSE Library.
    6. Najmiatul Fitria & Antoinette D. I. Asselt & Maarten J. Postma, 2019. "Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 407-417, April.
    7. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    8. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    9. Wendy Hens & Dirk Vissers & Nick Verhaeghe & Jan Gielen & Luc Van Gaal & Jan Taeymans, 2021. "Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis," IJERPH, MDPI, vol. 18(15), pages 1-13, July.
    10. Kim Edmunds & Penny Reeves & Paul Scuffham & Daniel A. Galvão & Robert U. Newton & Mark Jones & Nigel Spry & Dennis R. Taaffe & David Joseph & Suzanne K. Chambers & Haitham Tuffaha, 2020. "Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy," Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 727-737, October.
    11. Ingrid V Bassett & Darshini Govindasamy & Alison S Erlwanger & Emily P Hyle & Katharina Kranzer & Nienke van Schaik & Farzad Noubary & A David Paltiel & Robin Wood & Rochelle P Walensky & Elena Losina, 2014. "Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-11, January.
    12. Andrew Gawron & Dustin French & John Pandolfino & Colin Howden, 2014. "Economic Evaluations of Gastroesophageal Reflux Disease Medical Management," PharmacoEconomics, Springer, vol. 32(8), pages 745-758, August.
    13. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    14. José María Gutiérrez & Thierry Burnouf & Robert A Harrison & Juan J Calvete & Nicholas Brown & Simon D Jensen & David A Warrell & David J Williams & Global Snakebite Initiative, 2015. "A Call for Incorporating Social Research in the Global Struggle against Snakebite," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 9(9), pages 1-4, September.
    15. Frank G. Sandmann & Julie V. Robotham & Sarah R. Deeny & W. John Edmunds & Mark Jit, 2018. "Estimating the opportunity costs of bed‐days," Health Economics, John Wiley & Sons, Ltd., vol. 27(3), pages 592-605, March.
    16. Jesse Elliott & Sasha Katwyk & Bláthnaid McCoy & Tammy Clifford & Beth K. Potter & Becky Skidmore & George A. Wells & Doug Coyle, 2019. "Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations," PharmacoEconomics, Springer, vol. 37(10), pages 1261-1276, October.
    17. Wei Zhang & Aslam Anis, 2014. "Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now," PharmacoEconomics, Springer, vol. 32(5), pages 425-427, May.
    18. Damon, Maria & Zivin, Joshua Graff & Thirumurthy, Harsha, 2015. "Health shocks and natural resource management: Evidence from Western Kenya," Journal of Environmental Economics and Management, Elsevier, vol. 69(C), pages 36-52.
    19. Katherine Edwards & Natasha Jones & Julia Newton & Charlie Foster & Andrew Judge & Kate Jackson & Nigel K. Arden & Rafael Pinedo-Villanueva, 2017. "The cost-effectiveness of exercise-based cardiac rehabilitation: a systematic review of the characteristics and methodological quality of published literature," Health Economics Review, Springer, vol. 7(1), pages 1-23, December.
    20. Don Husereau & Michael Drummond & Stavros Petrou & Dan Greenberg & Josephine Mauskopf & Federico Augustovski & Andrew Briggs & David Moher & Elizabeth Loder & Chris Carswell, 2015. "Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration," PharmacoEconomics, Springer, vol. 33(5), pages 535-536, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pntd00:0004568. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosntds (email available below). General contact details of provider: https://journals.plos.org/plosntds/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.